Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apcmin/+mice

Neoplasia

Volumn 14, Issue 2, 2012, Pages 159-168

  Janakiram, Naveena B ^a   Mohammed, Altaf ^a   Qian, Li ^a   Choi, Chang In ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RETINOID X RECEPTOR ALPHA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CHEMOPROPHYLAXIS; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; GENOTYPE; HEMATOCRIT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; INTESTINE TUMOR; LIVER TOXICITY; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

EID: 84858010859     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111440     Document Type: Article

References (38)

1. American Cancer Society. Available at: http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuide/colorectal-cancer-key-statistics.
2. Naveena BJ, Indranie C, Altaf M, Steele VE, and Rao CV (2008). β-Ionone inhibits colonic aberrant crypt foci in rats, suppresses cell growth and induces retinoid X receptor α in human colon cancer cells. Mol Cancer Ther 7(1), 1-10.
3. Reddy BS, Hirose Y, Lubet R, Steele VE, Kelloff G, Paulson S, Seibert K, and Rao CV (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60(2), 293-297.
4. Smalley WE and DuBois RN (1997). Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39, 1-20.
5. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, and Sigman CC (1996). Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5(8), 657-666.
6. Zheng Y, Kramer PM, Olson G, Lubet RA, Steele VE, Kelloff GJ, and Pereira MA (1997). Prevention of by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis 18, 2119-2125.
7. Shalita AR (1987). Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 175, 151-157.
8. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, and Heyman RA (1996). Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56, 5566-5570.
9. Easwaran V, Pishvaian M, Salimuddin, and Byers S (1999). Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 9, 1415-1418.
10. Bugge TH, Pohl J, Lonnoy O, and Stunnenberg HG (1992). RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J 11, 1409-1418.
11. Froeschlé A, Carnac G, Alric S, Montarras D, Pinset C, Rochette-Egly C, and Bonnieu A (1996). RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells. Oncogene 12, 411-421.
12. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, and Narayan P (1994). Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59, 126-132.
13. Wu S, Zhang D, Zhang ZP, Soprano DR, and Soprano KJ (1998). Critical role of both retinoid nuclear receptors and retinoid-X receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid. Oncogene 17, 2839-2849.
14. Agarwal C, Chandraratna RA, Teng M, Nagpal S, Rorke EA, and Eckert RL (1996). Differential regulation of human ectocervical epithelial cell line proliferation and differentiation by retinoid X receptor- and retinoic acid receptor- specific retinoids. Cell Growth Differ 7, 521-530.
15. Bligh EG and Dyer WJ (1959). A rapid of total lipid extraction and purification. Can J Biochem Physiol 37, 911-917.
16. Min/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res 4, 2015-2026.
17. Li Y, Zhang Y, Hill J, Kim H-T, Shen Q, Bissonnette RP, Lamph WW, and Brown PH (2008). The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98, 1380-1388.
18. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, et al. (1996). Cyclooxygenase-2 over expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56, 2556-2560.
19. Jacoby RF, Seibert K, Cole CE, Kelloff G, and Lubet RA (2000). The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 60, 5040-5044.
20. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328, 1313-1316.
21. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342, 1946-1952.
22. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, and Brown PH (2002). Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11, 467-474.
23. Howell SR, Shirley MA, Grese TA, Neel DA, Wells KE, and Ulm EH (2001). Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. DrugMetab Dispos 29, 990-998.
24. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, et al. (1999). A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5, 1658-1664.
25. Sanal MG (2008). The blind men "see" the elephant-the many faces of fatty liver disease. World J Gastroenterol 14(6), 831-844.
26. Kim H-T, Kong G, DeNardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, et al. (2006). Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66, 12009-12018.
27. Koehne CH and Dubois RN (2004). COX-2 inhibition and colorectal cancer. Semin Oncol 31, 12-21.
28. Duplus E, Glorian M, and Forest C (2000). Fatty acid regulation of gene transcription. J Biol Chem 275, 30749-30752.
29. Nicolosi RJ, Woolfrey B, Wilson TA, Scollin P, Handelman G, and Fisher R (2004). Decreased aortic early atherosclerosis and associated risk factors in hypercholesterolemic hamsters fed a high- or mid-oleic acid oil compared to a high-linoleic acid oil. J Nutr Biochem 15, 540-547.
30. McKeown-Eyssen GE (1994). Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3, 687-695.
31. Koohestani N, Chia MC, Pham NA, Tran TT, Minkin S, Wolever TM, and Bruce WR (1998). Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy. Carcinogenesis 19, 1679-1684.
32. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, and Wakabayashi K (2003). Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 63, 6090-6095.
33. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, and Wakabayashi K (2003). Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR γ ligand. Cancer Sci 94, 960-964.
34. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, and Wakabayashi K (2005). Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA 102, 2970-2974.
35. Vu-dac N, Gervois P, Torra IP, Fruchart JC, Kosykh V, Kooistra T, Princen HM, Dallongeville J, and Staels B (1998). Retinoids increase human Apo C-III expression at the transcriptional level via the retinoid X receptor. J Clin Invest 102(3), 625-632.
36. Na S, Kang BY, Chung SW, Han S, Ma X, Trinchieri G, Im S, Lee JW, and Kim TS (1999). Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFκB. J Biol Chem 274, 7674-7680.
37. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, and Ellis LM (1999). Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1b. Br J Cancer 80, 1506-1511.
38. Petersen AM and Pedersen BK (2005). The anti-inflammatory effect of exercise. J Appl Physiol 98, 1154-1162.